About Atreca
Atreca is a company based in San Carlos (United States) founded in 2010. Atreca has raised $224.4 million across 9 funding rounds from investors including Gates Foundation, GSK and Tekla Capital Management. The company has 134 employees. Atreca operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Carlos, United States
- Employees 134
- Stage Public
- SectorsHealthcare
- Website atreca.com
- Social LinkedIn
- Legal Name Atreca, Inc.
- Total Equity Funding$224.4M (USD)
in 9 rounds
- Latest Funding Round$125M (USD), Series C
Sep 2018
- InvestorsGates Foundation
& 9 more
- Employee Count134
Funding Insights of Atreca
Atreca has successfully raised a total of $224.4M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $125 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $224.4M
- Total Rounds 9
- Last Round Series C — $125M
- First Round $160,000
(Nov 2011)
- Investors Count 10
All 9 funding rounds of Atreca with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2018 | $125M | Series C | – | Aisling Capital, EcoR1 | |
| Aug 2017 | $35M | Series B | – | Wellington | – |
| Oct 2015 | $57.26M | Series A | – | Gates Foundation, GSK | – |
| Aug 2013 | $700,000 | Seed | – | – | – |
| Jul 2012 | $6M | Seed | – | Gates Foundation | – |
| Apr 2012 | $40,000 | Seed | – | – | – |
| Mar 2012 | $50,000 | Seed | – | – | – |
| Feb 2012 | $350,000 | Seed | – | – | – |
| Nov 2011 | $160,000 | Debt – Conventional | – | – | – |
10 investors in total: 10 institutional.
Investors in Atreca
Atreca has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, GSK and Tekla Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in the US | – | aislingcapital.com | New York, United States | |
Venture capital funding is provided by Samsara BioCapital in California. | – | samsaracap.com | Palo Alto, United States | |
Biotech startups are funded by this venture capital firm. | – | boxercap.com | San Diego, United States | |
US focused VC firm | – | missionbaycapital.com | San Francisco, United States | |
Diversified investment management services are provided to institutional clients. | – | wellington.com | Boston, United States | |
- | – | ecor1cap.com | - | |
Investment advisory services are provided to financial clients. | 1986 | teklacap.com | Boston, United States | |
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom |
Investor details for Atreca
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Atreca
21 people are tracked at Atreca (4 in leadership, 12 in board & advisors, 5 in team); the tracked headcount is 134.
| Name | Role | Group |
|---|---|---|
Tito A. Serafini | Chief Strategy Officer & Founder | Leadership |
Jonathan Woo | Consultant, Co-founder | Leadership |
Jeff DeFalco | VP - Discovery Sciences | Leadership |
Stephen Gould | Chief Scientific Officer | Leadership |
Brian Atwood | Chairman | Board & advisors |
Stephen R. Brady | Director | Board & advisors |
David Lacey | Director | Board & advisors |
Lindsey Rolfe | Director | Board & advisors |
Franklin Berger | Director | Board & advisors |
Lori Kunkel | Advisor | Board & advisors |
William H. Robinson | Founder & Director | Board & advisors |
Lewis L. Lanier | Advisors | Board & advisors |
Mark M. Davis | Advisor | Board & advisors |
Lawrence Steinman | Advisor | Board & advisors |
Kristine M. Ball | Director | Board & advisors |
Lawrence Fong | Advisor | Board & advisors |
Courtney Phillips | General Counsel & Corporate Secretary | Team |
Xiaomu Chen | Scientist | Team |
Xiaobin Tang | Senior Scientist | Team |
Carlene Williams | Associate Scientist | Team |
1 more people are available in the full profile.
Complete people profiles for Atreca
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Atreca
4 dated milestones of Atreca across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Atreca is founded.
- Funding First funding round of $160K.
- Funding Latest funding round, Series C, of $125.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Atreca
Atreca operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Atreca
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Atreca
Complete news archive for Atreca
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Atreca
10 companies that operate in the same segment as Atreca (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Atreca
Atreca was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Atreca is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Atreca is a funded company, having raised a total of $224.4M across 9 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $160K, raised on Nov 2011.
Atreca has 134 employees.
Developer of antibody therapeutics for human anti-cancer immune responses. Atrecas proprietary Immune Repertoire Capture technology profiles a patients immune response at the single-cell level, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. Its technology can be used for the discovery and development of antibody-based therapeutics and for identifying the critical targets of effective immune responses. It is applying its technology to generate and develop a novel class of cancer immunotherapies including therapeutics that optimize anti-tumor immune responses in synergy with checkpoint inhibitors and immune activators.
Atreca's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Atreca has 10 investors. Key investors include Gates Foundation, GSK, Tekla Capital Management, Wellington, and Aisling Capital.
Atreca operates through Atreca, Inc..